LUPUS NEPHRITIS

This study tests a new drug called povetacicept in adults with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if the drug is safe and can help control these conditions. Participants receive the drug every 4 weeks for at least…

This early-stage study tests a new treatment called KYV-101 for people with lupus nephritis that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells that drive the disease. The study aims to chec…

This early-stage study tests a new treatment called CNTY-101 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myopathies that haven't responded to standard therapies. CNTY-101 uses specially engineered immune cells to target and destroy faulty …

This early-phase study tests a new treatment called KYV-101 for people with lupus nephritis (kidney inflammation from lupus) that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy harmful B cells. The main goal…

This early-phase study tests a new treatment called KITE-363 for people with severe autoimmune diseases like lupus, scleroderma, and inflammatory myositis that haven't improved with standard therapies. KITE-363 uses a patient's own immune cells, modified to target and destroy fau…

This study tests whether adding obinutuzumab to standard treatment helps people with lupus-related kidney disease (lupus nephritis). The trial includes 271 adults with active kidney inflammation. Researchers measure if the drug improves kidney function and reduces protein in urin…

This study was designed to test a single infusion of CB-010, a CRISPR-edited immune cell therapy, in people with severe lupus that did not respond to standard treatments. The trial was withdrawn before enrolling any participants, so no results are available. It aimed to check saf…

This study tests a drug called anifrolumab in 359 adults with active lupus nephritis, a serious kidney complication of lupus. The goal is to see if the drug can help the kidneys work better and reduce the need for steroids. Participants receive either the drug or a placebo, and r…

This early-stage study tests a new treatment for people with severe lupus or scleroderma that hasn't improved with standard therapies. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety and f…

This early-stage trial tests a treatment called YTB323 in about 21 adults with severe lupus that hasn't responded to other therapies. The goal is to see if it is safe and can help control the disease. Participants receive the therapy and are followed for side effects and how long…

This study tests a new drug, felzartamab, in 14 people with active lupus nephritis (kidney inflammation caused by lupus). The drug targets immune cells that make harmful antibodies, which build up in the kidneys and cause damage. Participants continue their usual treatments while…

This study aimed to test whether nipocalimab, an experimental drug, could help people with active lupus nephritis (kidney inflammation caused by lupus). The trial was planned for adults with confirmed kidney disease and high protein in their urine. However, the study was withdraw…

This early-phase study tests a new treatment called Prula-cel for people with certain autoimmune diseases like lupus and scleroderma. Prula-cel uses specially engineered immune cells from a healthy donor to target and attack faulty immune cells that cause disease. The main goals …